Safety and Effectiveness of Trastuzumab Biosimilar SB3 in Korean Patients, a Post-Marketing Surveillance Study

CONCLUSION: Safety and efficacy of SB3 demonstrated in this real-world study were comparable with previous studies of reference trastuzumab.PMID:37899039 | DOI:10.1159/000534626

Source: Oncology - October 29, 2023 Category: Cancer & Oncology Authors: Changwan Jeon Su Hwan Kang Sung-Bae Kim Nam-Sun Paik Ilkyun Lee Seung Ki Kim Eun Young Kim Gil Soo Son Young Bum Yoo Kyung-Hee Lee JeongSoo Shin Sungil Ju Harah Jang Min Ho Park Source Type: research